May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer May 31, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the United States Food and Drug… Read More
learn more
May 23, 2016

Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in… Read More
learn more
May 19, 2016

Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the INNOVATE trial,… Read More
learn more
May 18, 2016

Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients

Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Metastatic pancreatic cancer patients treated with TTFields therapy combined with gemcitabine had a median overall survival of 8.3 months May 18, 2016 05:00 PM… Read More
learn more
May 13, 2016

Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016

Results demonstrate that TTFields enhance immunogenic cell death in non-small cell lung cancer cells in vivo Data suggest combining TTFields with anti-PD-1 may achieve tumor control by further enhancing antitumor immunity May 13, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS… Read More
learn more
May 11, 2016

Novocure Enters into Employment Agreement with William Doyle

May 11, 2016 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today announced that it has entered into an employment agreement with William Doyle, current Chairman and Director, to formally establish his role… Read More
learn more
May 9, 2016

Novocure Reports First Quarter 2016 Financial Results and Provides Company Update

Increasing adoption of Optune with 755 prescriptions received in the first quarter 2016, an increase of 73 percent from the first quarter 2015 and 36 percent from the fourth quarter 2015 797 active patients at March 31, 2016, an increase of 114 percent from March 31, 2015… Read More
learn more
May 6, 2016

Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma

New programs respond to unmet needs described by the GBM community May 06, 2016 07:35 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today it will deliver new programs to support the glioblastoma (GBM) community during Brain Tumor Awareness Month. Last year,… Read More
learn more
May 5, 2016

Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer

Website and traveling exhibit to support glioblastoma community May 05, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today the availability of a new online resource to raise awareness of glioblastoma (GBM) and share stories of inspiration with the GBM… Read More
learn more
May 4, 2016

Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune

More than 112 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma May 04, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Blue Cross Blue Shield of Michigan now covers Optune… Read More
learn more